An Act To Amend The Laws Governing The Controlled Substances Prescription Monitoring Program
Maine law signed to amend prescription drug monitoring program rules, affecting how controlled substances prescriptions are tracked and managed statewide.
Maine law signed to amend prescription drug monitoring program rules, affecting how controlled substances prescriptions are tracked and managed statewide.
LD 765 amends Maine's Controlled Substances Prescription Monitoring Program (PMP) to modify how the state tracks and manages prescription opioids and other controlled substances. The bill has been signed into law as of April 22, 2025, and makes structural or operational changes to the existing prescription monitoring framework that healthcare providers and pharmacists must follow.
Prescription monitoring programs are critical public health tools designed to prevent prescription drug abuse, reduce opioid misuse, and identify patients seeking medications from multiple providers. Changes to Maine's PMP directly affect how effectively the state can combat prescription drug addiction and overdose deaths while balancing legitimate patient access to necessary medications.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.